Back to top
more

Akebia Therapeutics (AKBA)

(Real Time Quote from BATS)

$3.70 USD

3.70
731,188

-0.02 (-0.54%)

Updated Aug 4, 2025 11:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?

by Zacks Equity Research

Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.

Zacks Equity Research

Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.

Zacks Equity Research

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 200% and 26.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -4.76% and 48.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

by Zacks Equity Research

Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

by Zacks Equity Research

AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -25% and 18.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for January 3rd

by Zacks Equity Research

AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.

Zacks Equity Research

New Strong Sell Stocks for December 5th

by Zacks Equity Research

AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.

Zacks Equity Research

New Strong Sell Stocks for November 27th

by Zacks Equity Research

AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024.

Zacks Equity Research

New Strong Sell Stocks for November 22nd

by Zacks Equity Research

ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 18.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Consider Buying Akebia (AKBA) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.

Zacks Equity Research

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

by Zacks Equity Research

Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Innovation Reaches Peak

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

Zacks Equity Research

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

by Zacks Equity Research

Here is how Acrivon Therapeutics, Inc. (ACRV) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 33.33% and 4.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.